Effect of acetylcholinesterase inhibitors on the binding of nicotinic α4β2 receptor PET radiotracer, 18F‐nifene: A measure of acetylcholine competition
Abstract
Acetylcholinesterase inhibitors (AChEI's) are used to treat Alzheimer's disease (AD), and the putative mode of action is to increase acetylcholine (ACh) levels. Our goal is to evaluate competition of ACh with nicotinic α4β2 receptor PET agonist radiotracer, 2‐[18F]fluoro‐3‐[2‐((S)‐3‐pyrrolinyl)methoxy]pyridine (18F‐nifene). This ability to measure ACh‐18F‐nifene competition may have potential to assess efficacy of AChEI's in vivo. In vitro studies in rat brain slices used two AChEI's, physostigmine (PHY) and galanthamine (GAL). Brain slices were incubated with 18F‐nifene and various concentrations of PHY (0.2–20 μM) or GAL (0.4–4 μM) prior to 18F‐nifene treatment. For ACh competition, slices were also incubated with PHY + 100 nM ACh or GAL + 100 nM ACh or 100 nM ACh alone. Nonspecific binding of 18F‐nifene was determined using 300 μM nicotine. In the in vitro rat brain homogenate binding assay, ACh inhibited 3H‐cytisine binding to α4β2 receptors with Ki values of 19.2 nM (with PHY) and 34.7 μM (no PHY) indicating ∼1.8 × 103 weaker binding of ACh in the absence of AChEI. Binding of 18F‐nifene was not affected by PHY (0.2–20 μM) or ACh 100 nM alone but decreased substantially by PHY + ACh 100 nM in all brain regions (down by >40% of control in thalamus). Similarly, for GAL (4 μM) no effect on 18F‐nifene binding occurred but GAL (0.4–4 μM) + ACh 100 nM showed a reduction of 18F‐nifene binding in all brain regions (down by ∼15%). The reduction in both cases is a result of ACh competition with 18F‐nifene in the presence of AChEI. These preliminary in vitro results suggest that ACh is able to compete with 18F‐nifene at the α4β2 receptors in the presence of PHY or GAL. The effect is AChEI‐concentration dependent and is greater for PHY than GAL. Thus 18F‐nifene has promise for assessing ACh levels and AChEI effects in vivo. Synapse 61:29–36, 2007.Keywords
This publication has 25 references indexed in Scilit:
- Nicotinic α4β2 receptor imaging agentsNuclear Medicine and Biology, 2006
- In vivo butyrylcholinesterase activity is not increased in Alzheimer's disease synapsesAnnals of Neurology, 2005
- Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trialsBMJ, 2005
- Effect of fenfluramine-induced increases in serotonin release on [18F]MPPF binding: A continuous infusion PET study in conscious monkeysSynapse, 2005
- Sensitivity of [11C]N-methylpyrrolidinyl benzilate ([11C]NMPYB) to endogenous acetylcholine: PET imaging vs tissue sampling methodsNuclear Medicine and Biology, 2004
- Dopamine Depletion and In Vivo Binding of PET D1 Receptor Radioligands: Implications for Imaging Studies in SchizophreniaNeuropsychopharmacology, 2003
- Influence of acetylcholine levels on the binding of a SPECT nicotinic acetylcholine receptor ligand [123I]5‐I‐A‐85380Synapse, 2003
- Measuring nicotinic receptors with characteristics of α4β2, α3β2 and α3β4 subtypes in rat tissues by autoradiographyJournal of Neurochemistry, 2002
- In Vivo Imaging of Human Cerebral AcetylcholinesteraseJournal of Neurochemistry, 1996
- Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochemical Pharmacology, 1973